ChinaBio Today -- Last week, an acronym surfaced in China life science that hasn’t been heard much lately: IPO. Granted, it was only a rumor, and it was for a drug distribution company, not a drug manufacturer or, an even more unlikely event, for a drug discovery enterprise. But still, it was a sign – perhaps only an early sign – that the investment community’s disinterest in China life science may be coming to an end.
